As far back as the introduction of the HMO, the US health care system has been trying to find ways to incentivize high-value care and discourage low-value care. In this breakfast briefing, Bloomberg convenes health care sector CEOs, government, and thought leaders to discuss how escalating health care costs and the growing financial burden facing many patients are demanding greater acceleration of the move toward a value-driven health care system.
September 19 - Tuesday
Sponsor Spotlight: 5 Questions With...
Stephen J. Ubl
President & CEO, Pharmaceutical Research and Manufacturers of America (PhRMA)
Registration and Networking Breakfast
Collaborating on High-Value Care and Treatment
CEOs discuss the case for clearing the path toward a value-driven health care system, including evolving current infrastructure to support it. How can players across the health care system interact and change how care and treatment are paid for with a focus on rewarding what works for patients, and what technology, methods, regulations, and metrics are needed to capture and analyze information that will keep the movement toward value-driven care moving forward.
Co-anchor, "Bloomberg Markets Americas" & "Bloomberg Surveillance", Bloomberg
Delos M. Cosgrove
Chief Executive Officer & President, Cleveland Clinic
Executive Vice Chairman & Chief Executive Officer, Walgreens Boots Alliance
Ian C. Read
Chairman of the Board & Chief Executive Officer, Pfizer
Gary M. Reedy Gary M. Reedy
Chief Executive Officer, American Cancer Society, Inc.
How it works
Executives from a pharmaceutical company and a health care payer company, that are currently partnering on a value-based contract, share insights on how care and treatment are paid for with a focus on rewarding what works for patients. This discussion will focus on how these companies are innovating away from the traditional volume-based payment model to improve outcomes for patients, manage costs, and invest in better treatments for the future.
Team Leader U.S. Health Care, Bloomberg
Policy changes will continue to challenge the way the health care industry operates. In this fireside chat, we will explore how the system can insure that it continues to move towards value and is not held back while adjusting to these changes, and look to define what can be done to increase dynamism and drive progress in healthcare through partnerships, pilot programs, and funding initiatives.
Health Regulation Reporter, Bloomberg
Mark McClellanRobert J. Margolis Professor of Business, Medicine, and Policy & Director Duke-Margolis Center for Health Policy at Duke University
Amy P. Abernethy, M.D., Ph.D.Principal Deputy Commissioner of Food and Drugs FDA
Anna EdneyHealth Regulation Reporter Bloomberg
Harold L. PazExecutive Vice President and Chief Medical Officer Aetna
Joaquin DuatoExecutive Vice President and Chairman, Pharmaceuticals Johnson & Johnson
Drew ArmstrongTeam Leader U.S. Health Care Bloomberg
Gary M. Reedy Gary M. ReedyChief Executive Officer American Cancer Society, Inc.
Ian C. ReadChairman of the Board & Chief Executive Officer Pfizer
Stefano PessinaExecutive Vice Chairman & Chief Executive Officer Walgreens Boots Alliance
David GuraCo-anchor, "Bloomberg Markets Americas" & "Bloomberg Surveillance" Bloomberg
Stephen J. UblPresident & CEO Pharmaceutical Research and Manufacturers of America (PhRMA)
Delos M. CosgroveChief Executive Officer & President Cleveland Clinic
Biopharmaceutical innovation is advancing faster than ever before, and we need to make sure we have a payment and reimbursement system that is as innovative as the medicines. That is why the biopharmaceutical industry launched The Value Collaborative to bring researchers, caregivers, patients, payers and policymakers together to advance solutions that will enable the private sector to lead the move toward a value driven health care system.